CSF3R and cancer: We speculate that it may be possible that treatment with long-acting PEG-rhG-CSF can also cause CD4 + T cells and CD8 + T cells in patients with malignancies to express G-CSF receptors, which in turn can regulate T cells and elevate lymphocyte counts through these receptors.